wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
P2860
Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53740020-D00E4229-0563-44D0-85DC-01A96A6EFD50
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ecb52443f846a66e70421450a053ad004219fb47
P2860
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).